Related by context. All words. (Click for frequent words.) 76 IELT 63 serum testosterone 62 vaginal penetration 62 apnea hypopnea index 62 Crohn Disease Activity 62 NIH CPSI 61 Index CDAI 61 lumbar spine BMD 61 WOMAC pain 60 erection hardness 60 penile vaginal intercourse 60 QTc intervals 60 Scale EDSS score 60 corrected QT interval 60 serum urate 59 ejaculatory control 59 morphometric vertebral fractures 59 endometrial thickness 59 OGTT 59 CDAI score 59 recurrent VTE 59 dyspareunia 59 Hb A1C 59 oxycodone CR 59 hip BMD 58 creatinine clearance 58 serum prostate 58 #.#/#.# mmHg [001] 58 anogenital distance 58 MADRS score 58 ng dL 58 EDSS score 58 fluticasone salmeterol 58 peak VO2 58 serum estradiol 58 confidence intervals CIs 58 sUA 58 genital arousal 58 transaminase elevations 58 blood Phe levels 58 intraobserver 58 mL/min/#.# m 2 57 corticosteroid dose 57 urinary cortisol 57 evaluable subjects 57 lopinavir r arm 57 chronic prostatitis 57 MMSE score 57 oocytes retrieved 57 biochemical relapse 57 foveal thickness 57 PSA nadir 57 NIHSS score 57 attain statistical significance 57 Female Sexual Function 57 tipranavir r 57 MMSE scores 57 MetS 57 definite stent thrombosis 57 QTc 57 hemoglobin A1c HbA1c 57 albumin excretion rate 57 EBRT 57 periprocedural 57 gastric pH 57 serum bicarbonate 57 CD4 + cell 57 baseline HbA1c 57 AVODART 57 ipsilateral stroke 57 ADAS cog 57 abdominal pain abdominal discomfort 57 recurrent venous thromboembolism 57 annualized relapse 57 atorvastatin #mg 57 HBeAg seroconversion 57 μg liter 57 mIU ml 57 conjugated equine estrogen 57 alteplase 57 pCR 56 moderate renal impairment 56 baseline FEV1 56 6MWD 56 Severity MSCS score 56 thyrotropin levels 56 urine albumin 56 nonfasting triglyceride levels 56 HbA1C 56 extrapyramidal symptoms 56 BENICAR HCT 56 Visual Analogue Scale VAS 56 ARB telmisartan 56 #.#mmHg 56 benazepril 56 Heavy menstrual bleeding 56 Inventory BPI 56 depressive symptomatology 56 methacholine challenge 56 abdominal adiposity 56 postintervention 56 serum calcium levels 56 plus medroxyprogesterone acetate 56 HOMA IR 56 atrophic gastritis 56 serum phosphate 56 HDRS 56 Non inferiority 56 IM progesterone 56 highly emetogenic 56 severe exacerbations 56 PCWP 56 albumin excretion 56 achieved ACR# 56 GnRH agonist 56 serum concentrations 56 nonobese 56 virologic response 56 serum homocysteine 56 serum sodium 56 virologic failure 56 LUTS 56 aminotransferase elevations greater 56 glycated hemoglobin HbA1c 56 hypogonadal 56 brachial artery flow 56 ACR# responses 56 dose Iluvien 56 Fibromyalgia Impact Questionnaire 56 serum PSA 56 incontinence episodes 56 CK MB 56 carotid IMT 56 CI -#.# 56 hypogonadal men 56 acromegalic patients 56 CNS LS 56 complete cytogenetic response 56 fasting plasma glucose FPG 56 μmol L 56 angiographic restenosis 55 X ULN 55 QRS width 55 Y BOCS 55 luteal phase 55 alanine aminotransferase ALT 55 % CI #.#-#.# [003] 55 somatostatin analog 55 odds ratios ORs 55 mm Hg diastolic 55 prolonged QT interval 55 TLUS 55 QRS duration 55 vulvar vaginal 55 Cmax 55 QTc interval 55 perioperative mortality 55 dietary calcium intake 55 TEAEs 55 DAS# remission 55 urinary albumin 55 #mmHg [001] 55 HbA1C levels 55 CIN3 55 LEXIVA r 55 % Confidence Interval 55 HIV uninfected 55 esophageal acid 55 tapentadol IR 55 TT genotype 55 certolizumab 55 symptomatic VTE 55 #OHD 55 oxycodone IR 55 estimated GFR 55 HbA 1c 55 antibody titer 55 ZOMIG Nasal Spray 55 anemia hemoglobin 55 MoxDuo TM IR 55 mRS 55 rFSH 55 crossclamp 55 CC genotype 55 APTIVUS r 55 serum aminotransferase levels 55 specific antigen PSA 55 dapagliflozin plus 55 nonpregnant women 55 microg 55 serum urate levels 55 tacrolimus ointment 55 DAS# [002] 55 serum CRP 55 NATRECOR ® 55 PSD# 55 HbA 1c levels 55 salmeterol fluticasone propionate 55 Alzheimer Disease Assessment 55 achieved statistical significance 55 PSADT 55 azoospermia 55 mg eq 55 vaginal lubrication 55 mmHg diastolic 55 Scale EDSS 55 flutamide 55 -#.# log# copies mL 55 #mg doses [002] 55 antiandrogens 55 aged ≥ 55 SGPT 54 XIENCE V demonstrated 54 COMBIVIR 54 plasma folate 54 A1c levels 54 Cilostazol 54 clodronate 54 intima media thickness 54 urge incontinence 54 bioavailable testosterone 54 plasma leptin 54 loop diuretics 54 PANSS scores 54 menstrual bleeding 54 preoperative PSA 54 systemic corticosteroid 54 activated partial thromboplastin 54 Psoriasis Area 54 nmol L. 54 apnea hypopnea 54 salivary cortisol 54 premenstrual syndrome PMS 54 Cardiorespiratory fitness 54 ACR# ACR# 54 #q# deletion syndrome 54 detrusor overactivity 54 YMRS 54 CR nPR 54 CK # plasma concentrations 54 carotid stenosis 54 SpO 2 54 estimated glomerular filtration 54 Ishak fibrosis score 54 ml kg 54 PREZISTA r arm 54 spontaneous bowel movements 54 habitual snoring 54 NIHSS 54 arterial thickening 54 multivariable adjusted 54 BMI z 54 MADRS 54 Score DAS# 54 iPTH 54 Montgomery Asberg Depression 54 EDSS scores 54 HER2 expression 54 dizziness nausea diarrhea 54 blood Phe 54 trospium 54 nondepressed 54 symptom exacerbation 54 NATRECOR R 54 ± SD 54 mg BID dose 54 symptomatic intracranial hemorrhage 54 QALE 54 binary restenosis 54 urinary sodium excretion 54 maximal aerobic capacity 54 urinary albumin excretion 54 PLMS 54 ARIXTRA 54 CIN2 + 54 QTcF 54 Lupuzor ™ 54 urate lowering therapy 54 external genital lesions 54 budesonide pMDI 54 REMINYL ® 54 #mg/day [001] 54 NPH insulin 54 oxcarbazepine 54 ACR Pedi 54 cervicitis 54 Nocturia 54 #.#ng/ml 54 HAQ DI 54 serum folate concentrations 54 analgesic medications 54 perimenopausal women 54 timepoints 54 Infusion Reactions Severe 54 Serum creatinine 54 severe neutropenia 54 serologically active patients 54 alanine aminotransferase 54 dysmenorrhoea 54 x ULN 54 subscores 54 P = .# 54 PASI scores 54 prednisone prednisolone 54 antioxidant supplementation 54 prolactin levels 54 Pain Intensity 54 ALT elevations 54 SCIg 54 ertapenem 54 tipranavir ritonavir 54 multivariate Cox 54 adjunctive placebo 54 % CI #.#-#.# [005] 54 8mg/kg 54 interquartile range 54 urinary N telopeptide 54 gestational hypertension 54 statistically significant p = 54 abdominal circumference 54 CDAI 53 mean ± SEM 53 adverse reactions incidence 53 Prostate Specific Antigen 53 cTnT levels 53 aPTT 53 treat NNT 53 β blockers 53 calculated creatinine clearance 53 platelet reactivity 53 Pred Forte 53 insulin detemir 53 seroprotection 53 mg simvastatin 53 SIMPADICO 53 mmHg systolic 53 CVD mortality 53 serum IGF 53 overactive bladder symptoms 53 creatinine clearance CrCl 53 Kaplan Meier analysis 53 sd = 53 Montgomery Åsberg Depression 53 DAS# CRP 53 Thrombolysis 53 subclinical hypothyroidism 53 ABC/3TC 53 CHD mortality 53 intraclass correlation coefficient 53 FDA defined valvulopathy 53 amenorrhea 53 sinus tachycardia 53 radiographic progression 53 Premature ejaculation 53 urinary symptoms 53 RLS symptoms 53 mammographic density 53 IBDQ 53 serum phosphorous 53 BPH Symptom Score 53 PLMs 53 FSFI 53 neutrophil counts 53 virological response 53 baseline serum creatinine 53 serum uric acid 53 nonfatal MI 53 intraclass correlation coefficients 53 STRIDE PD 53 mediated dilation 53 severe renal impairment 53 hematologic toxicity 53 GERD symptoms 53 Skin sterol 53 methacholine 53 adenoma recurrence 53 vasomotor symptoms 53 mmol l 53 ventricular tachyarrhythmias 53 glycated hemoglobin 53 arterial thromboembolic events 53 CCyR 53 creatinine ratio 53 chloride secretion 53 HPA axis suppression 53 hypopnea 53 IPSS 53 aminotransferases 53 advanced adenoma 53 CrCl 53 Left Ventricular Ejection Fraction 53 SHBG levels 53 BENICAR 53 Betaferon R 53 androgen deprivation 53 posttreatment 53 oxyhemoglobin 53 IIEF 53 Erythropoietic therapies may 53 dalteparin 53 β blocker 53 ropinirole 53 liver enzymes ALT 53 OAB symptoms 53 ULORIC 53 follicular phase 53 del 5q MDS 53 nmol l 53 detrusor 53 ejection fractions 53 Viral load 53 systolic hypertension 53 ALT elevation 53 logistic regression analysis 53 vaginal atrophy 53 autoantibody levels 53 Expanded Disability Status 53 chlamydial infection 53 International Prostate Symptom 53 thyrotropin 53 serum creatinine levels 53 hours postdose 53 interobserver 53 AUC0 53 lispro 53 conditional logistic regression 53 micromolar 53 fasting plasma 53 PRADAXA #mg 53 hyperphenylalaninemia HPA due 53 #mg q8h 53 autonomic dysfunction 53 tapentadol ER 53 serum cortisol 53 UACR 53 VIIBRYD 53 XIENCE V PROMUS Stent 53 mEq L 53 systolic BP 53 serum phosphorus 53 prolactin elevation 53 prospectively stratified 53 interrater reliability 53 femoral neck BMD 53 cryptorchidism 53 protein excretion 53 cerebrovascular events 53 #μg [001] 53 sUA levels 53 indinavir 53 #mg #mg #mg [003] 53 varicoceles 53 reinfarction 53 MMSE 53 prospectively defined 53 hypertensives 53 tibolone 53 intravitreal injections 53 dysmenorrhea 53 physiological arousal 53 gout flares 53 VO2max 53 triglyceride concentration 53 salivary flow 53 ventricular tachyarrhythmia 53 SELENA SLEDAI score 53 #Gy 53 thromboembolic events 53 GnRH agonists 53 cTnT 53 preintervention 53 χ 53 antiandrogen 53 Available Seat Kilometres ASKs 53 anal incontinence 53 unprotected vaginal 53 â ‰ ¥ 53 liver histology 53 multivariate analyzes 53 histrelin 53 carotid intima media 53 serum triglycerides 52 SGOT 52 pulmonary capillary wedge 52 Brief Psychiatric 52 mcg BID 52 abnormal cytology 52 Rating Scale MADRS 52 #OHD levels 52 serum triglyceride 52 coronary calcification 52 serum ALT 52 nonsignificant difference 52 peak plasma concentrations 52 CI #.#-#.# [001] 52 colorectal adenoma 52 System IPSS 52 lumbar spine bone 52 nausea photophobia 52 mean baseline HbA1c 52 Viagra Sildenafil 52 angiotensin converting enzyme inhibitors 52 SUVmax 52 p = .# [002] 52 collected saliva samples 52 aspartate aminotransferase AST 52 hemoglobin Hb 52 MACCE 52 non pledgers 52 urinary tract symptoms 52 tamsulosin 52 COZAAR 52 Vagifem 52 PREZISTA ritonavir 52 % CI #.#-#.# [004] 52 ASCUS 52 periprocedural MI 52 adjunctive ABILIFY 52 troponin T 52 serum testosterone levels 52 dosing frequency 52 estim ated fewer 52 normal ULN 52 rectal gonorrhea 52 anovulatory 52 arterial elasticity 52 frequent awakenings 52 Primary endpoints 52 Score TOS 52 GH deficiency 52 Severity Index PASI 52 CPAP adherence 52 mg ustekinumab 52 asystole 52 mTSS 52 premenopause 52 #.#/#.# mm Hg [003] 52 Operative mortality 52 nmol L 52 clinically meaningful improvement 52 relapsed MM 52 CK # plasma 52 diastolic BP 52 nadroparin 52 TAXUS p value 52 cells μL 52 perioperative complications 52 plasma cortisol 52 estrogen deficiency 52 #.#mg/dL 52 lactate dehydrogenase LDH 52 Intraocular pressure 52 #ng/ml 52 nonvertebral fractures 52 interobserver reliability 52 steroid dexamethasone 52 recurrent miscarriage 52 BPH symptoms 52 multivariable Cox 52 Ejection Fraction 52 ADAS Cog 52 SSRI SNRI 52 tertile 52 glomerular filtration rate 52 univariate 52 atherogenic dyslipidemia 52 ancrod 52 lymphocyte count 52 abacavir lamivudine 52 Qmax 52 Hypogonadism 52 mm Hg systolic 52 desvenlafaxine succinate 52 mg/m2 dose 52 octreotide LAR 52 myocardial reperfusion 52 intact parathyroid hormone 52 hemorrhagic complications 52 Distress Scale 52 rizatriptan 52 LHRH agonists 52 isolated systolic hypertension 52 p = #.# [003] 52 ABCB1 52 oral prednisolone 52 nonfatal myocardial infarction 52 mcg QD 52 fraction LVEF 52 advanced neoplasia 52 moderately emetogenic 52 bronchial hyperresponsiveness 52 elevated ALT 52 Ramipril 52 systolic ejection 52 glycated hemoglobin levels 52 solifenacin 52 biochemical recurrence 52 statistical significance p 52 electrical cardioversion 52 msec 52 pulmonary exacerbation 52 plus methotrexate 52 tPSA 52 sumatriptan naproxen sodium 52 biphasic insulin aspart 52 μg dL 52 categorical variables 52 OSAHS 52 reperfusion therapy 52 repeat paracentesis 52 recurrent ischemia 52 gout flare 52 HRQoL 52 Secondary endpoints include 52 fasting insulin 52 expiratory flow 52 Depressive symptoms 52 nevirapine Viramune 52 Dyspnea 52 titrated glipizide 52 ADCS CGIC 52 uncircumcised males 52 WAIS III 52 REYATAZ r arm 52 nmol liter 52 subscore 52 aspartate aminotransferase 52 cerebral oxygen saturation 52 platelet inhibition 52 hemoglobin A1c levels 52 noninferiority 52 ± SEM 52 SerDes transceivers 52 TNSS 52 airflow obstruction 52 #mg/day [002] 52 Hypoactive Sexual Desire Disorder 52 hemagglutination inhibition 52 #mm Hg 52 baseline LDH 52 nonvertebral fracture 52 Myelosuppression 52 NHANES III 52 leukocyte count 52 chronic prostatitis chronic 52 Ischemic 52 fasting triglycerides 52 RLAI 52 3mg/kg 52 spirometric 52 mL kg 52 postoperative mortality 52 cecal intubation 52 Osteoporotic Fractures 52 Kaplan Meier estimates 52 serum LDL cholesterol 52 ACR# response 52 placebo p 52 salmeterol fluticasone 52 plasma homocysteine 52 daytime alertness 52 LS BMD 52 CIMZIA ™ 52 PASI score 52 Flu Cy 52 Secondary efficacy endpoints 52 ALT flares 52 Prelox 52 psychiatric comorbidities 52 somatic symptoms 52 overt nephropathy 51 micrograms mL 51 atherothrombotic events 51 atrioventricular block 51 pyridostigmine 51 serum bilirubin 51 daytime somnolence 51 median CD4 51 serum HCV RNA 51 urinary cadmium 51 secondary efficacy endpoint 51 adiponectin concentrations 51 receptive anal sex 51 penile sensitivity 51 Durezol 51 symptomatic DVT 51 paroxysmal AF 51 macroalbuminuria 51 cilostazol 51 safinamide 51 inhaled budesonide 51 Testosterone deficiency 51 Prostate Specific Antigen PSA 51 blood phenylalanine Phe 51 pg mL 51 Claudication 51 estrogen metabolites 51 bronchodilation 51 GERD symptom 51 EDARBI 51 #mg dose [002] 51 abnormal Pap test 51 #.#-#.# [011] 51 highest tertile 51 Score DAS 51 phytoestrogen intake 51 per deciliter mg 51 Score IPSS 51 Tasigna prolongs 51 alicaforsen enema 51 endometriosis ovarian cysts 51 HbA 1C 51 transdermal fentanyl 51 p = .# [001] 51 EXJADE 51 endometrial hyperplasia 51 fetal malformations 51 NYHA functional class 51 carotid artery intima media 51 LV dysfunction 51 thigh circumference 51 mL/min/#.# m2 51 serum potassium 51 racemic albuterol 51 methotrexate monotherapy 51 leukopenia 51 endometrial carcinoma 51 hematological parameters 51 plasma glucose levels 51 intensity aerobic exercise 51 neurocognitive function 51 IOP lowering 51 pegIFN 51 AUC0 #hr 51 zonisamide SR 51 death reinfarction 51 GnRH antagonist 51 ng dl 51 hypopneas 51 SGRQ 51 confidence interval #.#-#.# 51 elevated LDH 51 airflow limitation 51 doxorubicin docetaxel 51 oral glucose tolerance 51 -#.# mg dL [002] 51 T2 lesions 51 receptive anal intercourse 51 somnolence sleepiness 51 CorVue ™ 51 #.#ml [002] 51 irregular menstrual cycles 51 interrater 51 Hamilton Anxiety Scale 51 CANCIDAS 51 non menstrual pelvic 51 plasma fibrinogen 51 ejaculatory 51 treatment emergent AEs 51 asymptomatic carotid stenosis 51 rosuvastatin #mg 51 subjective sleepiness 51 Injury Severity Score 51 vaginal anal 51 receiving ISENTRESS 51 nondiabetic patients 51 fasting triglyceride levels 51 5-FU/LV 51 Lamictal XR 51 resuscitated cardiac arrest 51 #mmHg [002] 51 maximal oxygen 51 HoLEP 51 serum lipid levels 51 biologic DMARD 51 HBeAg negative 51 homocysteine concentrations 51 mg QD 51 Platelet counts 51 umol L 51 ACE inhibitor ramipril 51 duplex ultrasonography 51 baseline CD4 51 COPEGUS 51 androgen suppression 51 RAPTIVA 51 Mean Symptom Complex 51 pmol L 51 QT interval 51 plasma homocysteine levels 51 Enlarged prostate 51 epistaxis 51 cells mcL 51 thyroglobulin 51 ug dose 51 severe periodontitis 51 logistic regression analyzes 51 Ocular Surface Disease 51 DEXA scan 51 serum phosphate levels 51 κ 51 intraocular pressure IOP 51 Sleep disturbances 51 antimuscarinic 51 ACTEMRA TM 51 logistic regression model 51 vaginal progesterone gel 51 eplerenone 51 ximelagatran 51 irbesartan 51 Obstructive sleep apnea 51 nighttime awakenings 51 dexmedetomidine 51 DLQI 51 ALISTA 51 cortical activation 51 hypoglycemic events 51 tolterodine 51 EURIDIS 51 ibandronate 51 coronary revascularization procedures 51 lipid elevations 51 sinus bradycardia 51 carbidopa levodopa 51 apneic 51 log# copies mL 51 ARICEPT 51 CYP#D# inhibitor 51 varicocele 51 neurodevelopmental outcome 51 IRLS score 51 apneas 51 asthma exacerbation 51 FEV1 51 systemic embolism 51 ductal cancer 51 transferrin saturation 51 ARCALYST ® 51 Cronbach alpha 51 saline placebo 51 affective psychosis 51 FluCAM 51 androgen ablation 51 urinary calcium 51 aspirin clopidogrel 51 Hypotension 51 oral anticoagulation 51 receiving APTIVUS r 51 fractional shortening 51 D dimer 51 adenoma detection 51 submaximal 51 Zemplar Capsules 51 tertiles 51 deep venous thromboses 51 microalbuminuria 51 MMX mesalamine 51 QT intervals 51 hepatitis C genotype 51 Subgroup analysis 51 nocturia 51 Stent thrombosis 51 phonophobia 51 4mg/kg 51 placebo PBO 51 menopausal symptom 51 baseline PASI 51 spontaneous preterm delivery 51 post thrombotic syndrome 51 habitual snorers 51 FFNS 51 T1DM 51 Hazard Ratio HR 51 MIRP 51 serum calcium 51 Triglyceride levels 51 everolimus eluting stents 51 sustained virological response 51 Fasting plasma glucose 51 erythrocyte sedimentation rate 51 statistically significant p 51 Betaferon ® 51 overactive bladder OAB 51 ADCS ADL 51 Intermittent claudication 51 suicide attempters 51 weekly CSBMs 51 mmol L. 51 postprocedure 51 hsCRP 51 lowest tertile 51 dehydroepiandrosterone sulfate 51 ACR# [002] 51 BPH LUTS 51 bivariate analysis 51 pulmonary exacerbations 51 DOXIL 51 mcg kg REBETOL 51 Erectile Function 51 SCr 51 kcal d 51 MIRAPEX 50 hydroxyvitamin D levels 50 events TEAEs 50 thrombolytic therapy 50 glycosylated hemoglobin HbA1c 50 QT QTc 50 chronic pelvic 50 placebo dexamethasone 50 fructosamine 50 breast tenderness 50 Ophena TM 50 ziprasidone 50 severe hypoglycemia 50 TMC# r 50 histologically confirmed 50 atherothrombotic disease 50 haemorrhagic stroke 50 rt PA 50 linaclotide treated 50 symptom severity 50 baseline A1C 50 clinically meaningful reductions 50 vincristine doxorubicin 50 viral titers 50 divalproex sodium 50 euthymic patients 50 Zestra R 50 Bacterial vaginosis 50 mineral density 50 lipid lowering agents 50 teriflunomide 50 decrements 50 Sexual dysfunction 50 lymphocyte counts 50 Sumatriptan OS 50 PREZISTA r 50 Symptom severity 50 sub maximal 50 FACIT 50 APTIMA HPV 50 covariance ANCOVA 50 HbA1c levels 50 Renal Insufficiency 50 HAM D# scores 50 Index CDAI score 50 log# reduction 50 drank decaffeinated coffee 50 vertebral fracture 50 CIMZIA TM 50 NNRTI resistance 50 transdermal estradiol 50 RAPAFLO R 50 thrombocytopenic 50 neurologic complications 50 COMT genotype 50 statistically nonsignificant 50 lipid lowering drugs 50 bacterial vaginosis BV 50 Apgar scores 50 mg Pycnogenol 50 TURP 50 Engerix B 50 maximal treadmill 50 conduction velocity 50 oestradiol 50 isoproterenol 50 Perforomist Inhalation Solution 50 confidence interval CI 50 serum parathyroid hormone 50 placebo p = 50 PSD# spray 50 haematological toxicity 50 serum PTH 50 adenotonsillectomy 50 = #.#-#.# 50 HMG CoA reductase inhibitory 50 fosamprenavir 50 atrial pacing 50 Aggrenox ® 50 mg p = 50 #.#mmol L [002] 50 % CI #.#-#.# [007] 50 carotid endarterectomy CEA 50 bothersome symptom 50 hormonal fluctuation 50 eszopiclone 50 FAMPYRA 50 partial thromboplastin 50 ml min 50 fasting glucose levels 50 subclinical hyperthyroidism 50 Thorough QT 50 DULERA 50 HAM D# 50 PSVT 50 + PH# 50 MSLT 50 hypovolemia